Capital Tie-up with Kaigen Pharma

ORTHOREBIRTH has recently entered into the Capital Tie-up Agreement with Kaigen Pharma. This is followed by our conclusion of the Basic Agreement with Kaigen Pharma regarding contract manufacturing of our flagship, ReBOSSIS (the world’s first cottony type, synthetic bone-void-filling material) back in October in 2015. Through this capital tie-up agreement, the both companies are highly expected to establish a further deeper business partnership with each other. For example, the production of ReBOSSIS is going to start at Kaigen Pharmer’s Factory in Otaru, Hokkaido this summer. The photo shows the May-9 Nikkei article reporting this capital tie-up.